This newest twist in the Lykos Therapeutics saga threatens A significant overhaul of the corporate’s system and direction, with Musk ally and billionaire investor Antonio Gracias appearing to wish to take the corporation again toward its nonprofit drug development roots and a more Doblinite philosophy.This week in copyright enterprise news: Wesan